TSOI News 11-1-2021

This forum is to discuss general things concerning TSOI.
Codycrusher
Posts: 250
Joined: Sat Feb 13, 2021 2:29 pm

Re: TSOI News 11-1-2021

Post by Codycrusher »

So you would have to request a whole new phase 1 IND trials with the fda right for this antibody? You would have to take this through the FDA process as it’s own unique treatment like the rest right?
curncman
Posts: 1157
Joined: Fri Jun 26, 2020 8:27 am

Re: TSOI News 11-1-2021 COVID breakthrough data reveals WHO is at risk

Post by curncman »

Thanks Tim for clarifying this dumb brain :lol: :lol: :lol: :lol:

Who Had COVID-19 Vaccine Breakthrough Cases?
Image

WITH STORY: BC-VIRUS-BREAKTHROUGHS-NYT After a summer of reports of breakthrough coronavirus infections, when it seemed that everyone knew someone who tested positive after vaccination, recently released federal data sheds light on how common these cases really were, how severe they became and who was most at risk. -- 8.5x5.5 -- cat=a..
After a summer of reports of breakthrough coronavirus infections, when it seemed that everyone knew someone who tested positive after vaccination, recently released federal data sheds light on how common these cases really were, how severe they became and who was most at risk.

Compared with the unvaccinated, fully vaccinated people overall had a much lower chance of testing positive for the virus or dying from it, even through the summer’s delta surge and the relaxation of pandemic restrictions in many parts of the country. But the data indicates that immunity against infection may be slowly waning for vaccinated people, even as the vaccines continue to be strongly protective against severe illness and death.

“The No. 1 take-home message is that these vaccines are still working,” said Dr. David Dowdy, a public health researcher at the Johns Hopkins Bloomberg School of Public Health. “If you saw these data for any disease other than COVID, what everyone’s eyes would be drawn to is the difference between the unvaccinated and fully vaccinated lines.”

Sign up for The Morning newsletter from the New York Times

The data shows notable differences in breakthrough death rates by age and slight differences in both case and death rates by vaccine brand, trends that experts say are important to consider as tens of millions of Americans weigh whether to get a booster shot.

The data, from the Centers for Disease Control and Prevention, is based on health department records from 14 states and two cities. A second dashboard reveals similar trends for hospitalized patients with and without vaccination.

All vaccinated age groups saw similar rates of breakthrough infection, and they all had much lower rates of infection and death compared with their unvaccinated peers.

While every age group had similar rates of breakthrough cases, death rates varied more drastically by age. Unvaccinated seniors were the most likely to die from COVID of any group. Still, vaccinated people 80 and older had higher death rates than unvaccinated people under 50.

“Age is our top risk factor for vaccine breakthrough deaths,” said Theresa Sokol, the state epidemiologist in Louisiana, one of the jurisdictions that contributed to the CDC data.

Breakthrough deaths among seniors may be because of immunosenescence, or the weakening of the immune system in older people, said Heather Scobie, a public health researcher at the CDC who helps lead the team that produced the new data.

“They don’t usually form as robust a response to vaccination,” added Scobie. “Hopefully the booster dose for ages 65 years and older will address that issue.”

The federal data also makes it clear that all three brands of vaccine administered in the United States substantially reduced rates of cases and deaths. But among those vaccinated, Johnson & Johnson recipients had slightly higher rates of breakthrough cases and related deaths. And Pfizer-BioNTech recipients had slightly higher rates than those who got Moderna.

Similar data from scientific studies helped shape the new federal recommendation that all Johnson & Johnson recipients, 18 and older, receive a booster dose at least two months after getting the first shot, Scobie said.

In contrast, booster shot recommendations for those who got the Pfizer or Moderna vaccine are focused on high-risk groups, including those over 65, and younger adults at greater risk of severe COVID-19 because of medical conditions or where they work.

The CDC data, which will be updated monthly, is the closest yet to a detailed, nationally representative view of breakthrough cases and deaths. States are not required to report this information — though many do in myriad formats — and the CDC had previously only provided estimates of total breakthrough hospitalizations and deaths.

The data can also give scientists a crude understanding of the effectiveness of the vaccine over time. If the ratio of cases or deaths among the unvaccinated to those among the vaccinated holds steady, the vaccines are thought to be maintaining their protection.

For example, the ratio of case rates declined somewhat in the summer, to six times as high for the unvaccinated in August from about 11 times as high in mid-June, giving scientists reason to believe that the vaccine’s protection against infection might be waning slightly. The ratio for deaths has been flatter over time for all but the oldest age groups, an indication that vaccine protection against death is holding strong.

The CDC data so far runs through early September and captures only the crest of the delta wave. But data from states like New York and California shows similar patterns through September and October. That suggests that the vaccines, despite some slight differences among the brands, are still working to protect against the most severe outcomes.



Note: The data excludes partially vaccinated people. Overall rates are age-adjusted to make the fully vaccinated and unvaccinated populations more comparable. Data includes reports from Alabama, Arizona, Arkansas, Colorado, Florida, Georgia, Idaho, Louisiana, Massachusetts, Michigan, Nebraska, New Mexico, New York City, Seattle, Utah and Wisconsin.

Sources: Centers for Disease Control and Prevention; Outbreak.info (date when delta variant became dominant)

© 2021 The New York Times Company
craigdunn63
Posts: 28
Joined: Sun Aug 22, 2021 11:33 pm

Re: TSOI News 11-1-2021

Post by craigdunn63 »

Tim I think it’s brilliant not to post pr’s to TD Ameritrade accounts etc…
It’s like throwing precious pearls in a slop full of swine.
However the outlets you listed will draw in real, solid, long term investors and not just a bunch of penny flipping Pumpers who, well only care about fda or Eua.

You could post that your growing legs for orphan babies and some penny flippen goofball would say “ yeah but when’s Eua gonna be approved. 😩😡

Move along lad… this isn’t your stop 🤣
User avatar
TimGDixon
Posts: 2661
Joined: Fri Jun 26, 2020 4:36 am

Re: TSOI News 11-1-2021

Post by TimGDixon »

Bingo Craigdunn63.
craigdunn63 wrote: Mon Nov 01, 2021 11:55 pm Tim I think it’s brilliant not to post pr’s to TD Ameritrade accounts etc…
It’s like throwing precious pearls in a slop full of swine.
However the outlets you listed will draw in real, solid, long term investors and not just a bunch of penny flipping Pumpers who, well only care about fda or Eua.

You could post that your growing legs for orphan babies and some penny flippen goofball would say “ yeah but when’s Eua gonna be approved. 😩😡

Move along lad… this isn’t your stop 🤣
SgtSki1010
Posts: 447
Joined: Thu May 13, 2021 6:17 pm

Re: TSOI News 11-1-2021

Post by SgtSki1010 »

User avatar
TimGDixon
Posts: 2661
Joined: Fri Jun 26, 2020 4:36 am

Re: TSOI News 11-1-2021

Post by TimGDixon »

Time to get back to science. I thought I would share one of the experiments we conducted in our R&D for TSOI-576. This antibody, being bispecific, can do two things at once. It can reduce pulmonary inflammation and cause morphogenesis within the lung to create new lung cells.

An ongoing problem in antibody technologies is the desire for "bispecific" antibodies that bind to two (or more) different antigens simultaneously, in general, allowing the different antigens to be brought into proximity, resulting in new functionalities and new therapies. We have achieved that here and like everything else this will need to endure rigorous clinical trials.

One of the major pathologies of COVID-19 is the opening of the endothelial gap junctions allowing for fluid to enter the extracapillary spaces. This results in fluid accumulating in the alveoli, which makes breathing compromised, even in some cases during mechanical ventilation.

The TSOI-576 antibody was administered intravenously into BALB/c mice treated with 100 nanograms of endotoxin per mouse. Endotoxin functions by binding to toll like receptor 4 and causes a pathology that has been reported to be similar to COVID-19 induced ARDS. The lung weight of the animal was measured at time points of zero, 12 hours and 24 hours. Ten mice per group were assessed for the experiment. As can be seen, a significant dose-dependent suppression of pulmonary inflammation was seen as resulted of the antibody treatment. Additionally, examination of the lungs revealed TSOI-576 also resulted in dose-dependent suppression of neutrophil infiltration, interleukin-6 content in the lung and overall suppression of fibrosis in mice allowed to live 4 weeks and assessed for fibrotic tissue content by hydroxyproline staining.

576-3.png
576-3.png (150.53 KiB) Viewed 152 times
strawpatch
Posts: 44
Joined: Sun Jun 28, 2020 11:40 am

Re: TSOI News 11-1-2021

Post by strawpatch »

That's impressive preclinical support for TSOI-576, thanks for sharing it with the community Tim.
DebG53
Posts: 65
Joined: Mon Sep 27, 2021 12:23 pm

Re: TSOI News 11-1-2021

Post by DebG53 »

Tim, I don't have a scientific braincell anywhere in my brain (will quad and projuvenol help with that? :lol: ) But Dennis said just check out the chart. Anyway, I know this is all great news and I'm just so thankful for you, Tom and the team- for not giving up on us here in the forum and for always keeping us as informed as you are able to do. I know that there is a lot you legally cannot share and most of us understand and respect that. You are an awesome CEO and I feel blessed to own a small portion of this stock.

I pray you'll have a wonderful Thanksgiving week and that you'll find some time to rest and enjoy family time.

Be blessed!
Be Blessed, everyone. The future looks great.
Debbie
User avatar
TimGDixon
Posts: 2661
Joined: Fri Jun 26, 2020 4:36 am

Re: TSOI News 11-1-2021

Post by TimGDixon »

Thanks Strawpatch. We think our most fertile path forward with this is to begin in academia which means grants need to be obtained so this isn't an overnight thing and will take a while but you have to start somewhere and preclinical was novel enough that we filed the IP. BTW this is the only bispecific antibody capable of doing this that we are aware, at least as of filing to today.
strawpatch wrote: Sat Nov 20, 2021 9:40 am That's impressive preclinical support for TSOI-576, thanks for sharing it with the community Tim.
User avatar
TimGDixon
Posts: 2661
Joined: Fri Jun 26, 2020 4:36 am

Re: TSOI News 11-1-2021

Post by TimGDixon »

Thank you for the Thanksgiving wishes and hope you and Dennis also have a great time. There are only so many things I can actually discuss and maintain a stack of nda's. I think sometimes folks forget about these things and think I am being coy or whatever when I'm trying to be polite about it.
DebG53 wrote: Sat Nov 20, 2021 10:06 am Tim, I don't have a scientific braincell anywhere in my brain (will quad and projuvenol help with that? :lol: ) But Dennis said just check out the chart. Anyway, I know this is all great news and I'm just so thankful for you, Tom and the team- for not giving up on us here in the forum and for always keeping us as informed as you are able to do. I know that there is a lot you legally cannot share and most of us understand and respect that. You are an awesome CEO and I feel blessed to own a small portion of this stock.

I pray you'll have a wonderful Thanksgiving week and that you'll find some time to rest and enjoy family time.

Be blessed!
Post Reply